welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
A Device for Rapid, Painless, Bedside Muscle Evaluation of Children
study id #: NCT02340923
condition: Duchenne Muscular Dystrophy
The purpose of this protocol is to perform Electrical Impedance Myography (EIM) testing on healthy children and children with duchenne muscular dystrophy so as to develop a new, convenient tool for the office based assessment of children with a wide variety of neuromuscular conditions.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: January 2015
estimated completion: June 2016
size / enrollment: 327
- Electrical Impedance Myography Measurements [ Time Frame: Baseline (all subjects) & 3 months, 6 months, 1 year for returning subjects only ]
Up to 11 muscles will be measured using EIM technology. These muscles include: Right Lateral Deltoid, Right Biceps, Right Triceps, Right Wrist Flexors, Right Wrist Extensors, Right Vastus Lateralis, Right Tibialis Anterior, Right Gastrocnemius, Right Gluteus Medius, Right Biceps Femoris, and Right Thoracic Parapinal.
• Age 0-18
• Genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member.
• Age over 18
• Presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
European Home Mechanical Ventilation RegistryThe European Home Mechanical Ventilation...
Stomatognathic function in Duchenne muscular dystrophy: a case-control studyAim: This study aimed to analyse electr...
The Duchenne Registry (Previously DuchenneConnect)The Duchenne Registry is an online, pati...
Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of LifeThe study will give a consent based epid...
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award WinnersSOUTH PLAINFIELD, N.J., Sept. 6, 2019 ...
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular DystrophyThis study is being performed as a post-...
DMD clinical therapies II: P.135 DMD-HUB: expanding clinical trial capacity for Duchenne muscular dystrophy, 1 year ...The need to increase capacity for Duchen...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...